| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
DT-216P2 Anticipated Milestones: Registrational Plan Update in Q4 2026 and 12-Week RESTORE-FA Data in Q1 2027 |
| 03 Aug 2026 |
8-K: Results of Operations and Financial Condition
RESTORE-FA trial modifications build on positive four-week data; expect to share data based on 12 weeks of dosing in the first quarter of 2027 |
| 11 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 9, 2026, Design Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 14, 2026, the record date for the Annual Meeting, 62,441,429 shares of common stock were outstand... |
| 18 May 2026 |
8-K: Other Events
On May 18, 2026, Design Therapeutics, Inc. (the “Company”) announced biomarker and clinical data from the ongoing Phase 1/2 RESTORE-FA trial evaluating DT-216P2 in patients with Friedreich ataxia (“FA”). |
| 28 Apr 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints |
| 01 Apr 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 09 Mar 2026 |
8-K: Results of Operations and Financial Condition
Trials for DT-216P2 (RESTORE-FA) and DT-168 (FECD) Ongoing; DT-818 (DM1) Dosing in Patients Expected in the First Half of 2026 |
| 30 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
Design Therapeutics Announces Plans to Initiate Patient Dosing of DT-818 in Myotonic Dystrophy Type-1 (DM1) in the First Half of 2026 and Reports Third Quarter 2025 Financial Results |
| 10 Sep 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 07 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
Early Human Pharmacokinetics Data for DT-216P2 Demonstrates Favorable Translation from non-human primates (NHPs) to Humans and Improved DT-216 Product Profile for Friedreich Ataxia (FA) Program |
| 12 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 10, 2025, Design Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 15, 2025, the record date for the Annual Meeting, 56,768,678 shares of common stock were outstan... |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing |
| 10 Mar 2025 |
8-K: Results of Operations and Financial Condition
Design Therapeutics Highlights Progress Across Lead GeneTAC® Programs and Reports Fourth Quarter and Full Year 2024 Financial Results |
| 13 Jan 2025 |
8-K: Regulation FD Disclosure
On January 13, 2025, Design Therapeutics, Inc. (the “Company”) updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the updated presentation is attached as Exhibit 99.1 to this Current Rep... |
| 07 Nov 2024 |
8-K: Results of Operations and Financial Condition
Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio |
| 05 Aug 2024 |
8-K: Results of Operations and Financial Condition
Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio |
| 17 Jun 2024 |
8-K: Submission of Matters to a Vote of Security Holders
On June 13, 2024, Design Therapeutics, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). As of April 18, 2024, the record date for the Annual Meeting, 56,495,039 shares of common stock were outstan... |
| 08 May 2024 |
8-K: Results of Operations and Financial Condition
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials |
| 19 Mar 2024 |
8-K: Results of Operations and Financial Condition
Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results |
Loading...